Number of the records: 1  

Are Changes in the Percentage of Specific Leukocyte Subpopulations Associated with Endogenous DNA Damage Levels in Testicular Cancer Patients?

  1. TitleAre Changes in the Percentage of Specific Leukocyte Subpopulations Associated with Endogenous DNA Damage Levels in Testicular Cancer Patients?
    Author Kaľavská Katarína 1987- SAVBIOMED - Biomedicínske centrum SAV
    Co-authors Šestáková Zuzana 1983- SAVBIOMED ; SAVEXONK - Biomedicínske centrum SAV    ORCID

    Mlčáková Andrea 1977-

    Kozics Katarína 1977- SAVBIOMED ; SAVEXONK - Biomedicínske centrum SAV

    Gronesová Paulína 1982- SAVBIOMED ; SAVEXONK - Biomedicínske centrum SAV

    Hurbanová Lenka SAVBIOMED ; SAVEXONK - Biomedicínske centrum SAV

    Miškovská V.

    Rejleková Katarína

    Svetlovská D.

    Sycova Mila Zuzana

    Obertová Jana

    Palacka Patrik

    Mardiak Jozef

    Chovanec Michal

    Chovanec Miroslav 1969- SAVBIOMED ; SAVEXONK - Biomedicínske centrum SAV

    Mego Michal SAVBIOMED ; SAVEXONK - Biomedicínske centrum SAV

    Source document International Journal of Molecular Sciences. Vol. 22, no. 15 (2021), art. no 8281
    Languageeng - English
    CountryCH - Switzerland
    Noteopen access
    URLURL link
    Document kindrozpis článkov z periodík (rbx)
    CitationsRANASINGHE, R. - MATHAI, M.L. - ZULLI, A. Cisplatin for cancer therapy and overcoming chemoresistance. In HELIYON. SEP 2022, vol. 8, no. 9. Dostupné na: https://doi.org/10.1016/j.heliyon.2022.e10608.
    CategoryADCA - Scientific papers in foreign journals registered in Current Contents Connect with IF (impacted)
    Category of document (from 2022)V3 - Vedecký výstup publikačnej činnosti z časopisu
    Type of documentčlánok
    Year2021
    Registered inWOS
    Registered inSCOPUS
    Registered inCCC
    DOI 10.3390/ijms22158281
    article

    article

    rokCCIFIF Q (best)JCR Av Jour IF PercSJRSJR Q (best)CiteScore
    A
    rok vydaniarok metrikyIFIF Q (best)SJRSJR Q (best)
    202120205.924Q11.455Q1
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.